Here’s a story about a stock that’s been a bit of a laggard getting a fresh look from an analyst who thinks it might be time for a comeback. Enovis Corporation (ENOV) just got initiated with an Outperform rating by William Blair on Friday. The main thesis? Free cash flow is about to get a whole lot better, and that could be the key to unlocking some value.
The firm’s argument is pretty straightforward: while the stock has underperformed over the past two years, getting the cash flow story right could lead to what they call "multiple expansion opportunities." In plain English, if Enovis starts generating more cash, investors might be willing to pay more for each dollar of its earnings. Right now, shares trade at roughly 9 times trailing earnings (including stock-based compensation), compared with about 15.5 times for its peers. That gap highlights what William Blair calls "persistent investor skepticism."
What’s Been Holding the Stock Back?
So why has Enovis been stuck in the penalty box? The analyst points to two main things: uneven quarterly growth in U.S. hip and knee procedures, and concerns around free cash flow generation. It’s the classic "growth is choppy and the cash isn’t flowing" problem that tends to make investors nervous.
But management is trying to turn that around. They’ve guided to free cash flow conversion of about 25% in 2026, which is a big jump from 10% in 2025. William Blair thinks that target is achievable, largely because they expect several cash-related charges from the prior year to decline. It’s one of those "the worst is behind us" scenarios that analysts love to bet on.
A More Conservative Growth Outlook
On the revenue side, Enovis has dialed back expectations a bit. Management is now projecting 4% to 6% underlying revenue growth for 2026. That’s a step down from the 6%+ growth they were expecting for 2024 and 2025. William Blair forecasts 5.2% underlying sales growth for 2026, which lines up nicely with the company’s reset. Sometimes setting a lower bar isn’t a bad thing—it just means you have a better shot at clearing it.
The Arvis Relaunch: A New Growth Engine?
One of the more interesting parts of the story is the relaunch of the Arvis augmented reality surgical guidance system for knee replacements. Think of it as a high-tech assist for surgeons. The platform is positioned as a cost-effective and flexible alternative to robotic systems, which could make it particularly appealing to ambulatory surgery centers. The analyst also sees an opportunity for Enovis to gain market share while some of its larger competitors are going through transitions. In a competitive market, sometimes the best time to make a move is when everyone else is distracted.
Recent Results: A Mixed Bag
Let’s look at the most recent report card. In the fourth quarter, Enovis reported net sales of $576 million, up 3% on a reported basis and 2% organically. The growth was driven by the Global Reconstructive segment, while the Prevention & Recovery segment remained stable. More specifically, Recon sales rose 7% reported (3% organic), while P&R declined 1% reported and was flat organically.
Now, here’s the not-so-great part: the company posted a net loss of $519 million. But before you panic, most of that—$501 million—was due to a non-cash goodwill impairment charge. It’s one of those accounting things that hurts the bottom line on paper but doesn’t actually cost any cash. Adjusted EBITDA came in at $112 million, with adjusted earnings per share of 95 cents.
The Road Ahead for 2026
Looking forward, Enovis expects revenue in the range of $2.31 billion to $2.37 billion for 2026, which implies that 4% to 6% organic growth. Adjusted EBITDA is projected to be between $425 million and $435 million, with adjusted EPS in the range of $3.52 to $3.73. It’s a steady improvement story, not a moonshot.
As for the stock’s reaction? Enovis shares were up 6.51% at $26.84 at the time of publication on Friday, according to market data. Sometimes a little analyst love is all it takes to get things moving.
